KMT2A and acute myeloid leukemia: Overall, this method was able to exclude AML associated with t(8;21), t(15;17), inv(16)/t(16;16), and KMT2A(MLL) translocation with 92% sensitivity (95% CI: 78.6%–98.3%), a 98.5% negative predictive value (95% CI: 90.6%–99.8%), and a likelihood ratio for a negative test of 0.04 (95% CI: 0.01–0.28).